Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR2 | O15552 | 1/20 | 0.32 |
| ▸ | VNN1 | O95497 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3108505 | 0.85 | TAAR1 (0.42) | CHRM2CHRM1CHRM3NPC1TAAR1 | |
| SCHEMBL22597884 | 0.80 | VNN1 (0.32) | VNN1CHRM2CHRM1CHRM3NPC1 | |
| SCHEMBL12885030 | 0.78 | SMN1; SMN2 (0.49) | CHRM2CHRM1CHRM3NPC1SMN1; SMN2 | |
| SCHEMBL2606122 | 0.78 | SMN1; SMN2 (0.49) | CHRM2CHRM1CHRM3NPC1SMN1; SMN2 | |
| SCHEMBL12885025 | 0.78 | SMN1; SMN2 (0.49) | CHRM2CHRM1CHRM3NPC1SMN1; SMN2 | |
| SCHEMBL771441 | 0.77 | SIGMAR1 (0.35) | NPC1 | |
| SCHEMBL19951600 | 0.77 | — | — | |
| SCHEMBL356232 | 0.77 | — | — | |
| SCHEMBL12464725 | 0.76 | CYP3A4 (0.44) | CHRM2CHRM1CHRM3NPC1 | |
| SCHEMBL20284617 | 0.76 | FFAR2 (0.32) | FFAR2VNN1CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | AGOURON PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | CA2, CA7, CA9 | FFAR2 3453/4885VNN1 2951/4885CHRM2 3715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.